Xeriant (XERI) 10-K16 Oct 232023 FY Annual reportFinancial data

Company Profile

Cover

Cover - USD ($) $ in Millions	12 Months Ended
Cover - USD ($) $ in Millions	Jun. 30, 2023	Oct. 12, 2023	Dec. 31, 2022
Cover [Abstract]
Entity Registrant Name	XERIANT, INC.
Entity Central Index Key	0001481504
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--06-30
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		401,033,144
Entity Public Float			$ 30.4
Document Annual Report	true
Document Transition Report	false
Document Fin Stmt Error Correction Flag	false
Entity File Number	000-54277
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	27-1519178
Entity Address Address Line 1	Innovation Centre 1 3998 FAU Boulevard
Entity Address Address Line 2	Suite 309
Entity Address City Or Town	Boca Raton
Entity Address State Or Province	FL
Entity Address Postal Zip Code	33431
City Area Code	561
Icfr Auditor Attestation Flag	false
Auditor Name	Accell Audit & Compliance, PA
Auditor Location	Tampa, Florida
Local Phone Number	491-9595
Security 12g Title	Common Stock, $0.00001 par value
Entity Interactive Data Current	Yes
Auditor Firm Id	3289

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Current assets
Cash	$ 61,625	$ 1,065,945
Prepaids	4,529	756
Total current assets	66,154	1,066,701
Deposits	12,546	12,546
Property & equipment, net	5,507	4,409
Operating lease right-of-use asset	82,911	128,342
Investment in JV with Ebenberg LLC	0	57,678
Total assets	167,118	1,269,676
Current liabilities
Accounts payable and accrued liabilities	402,568	56,836
Accrued liabilities, related party	20,000	22,000
Shares to be issued	75,200	75,200
Convertible notes payable, net of discount - in default	5,850,000	3,936,185
Convertible notes payable, net of discount	100,000	0
Convertible bridge loans, at fair value	247,254	0
Lease liability, current	55,999	48,963
Total current liabilities	6,751,021	4,139,184
Lease liability, long-term	36,197	92,197
Total liabilities	6,787,218	4,231,381
Stockholders' deficit
Common stock, $0.00001 par value; 5,000,000,000 shares authorized; 389,433,144 and 365,239,001 shares issued and outstanding at June 30, 2023 and 2022, respectively	3,894	3,652
Common stock to be issued	51,950	51,950
Additional paid in capital	19,789,793	16,351,791
Accumulated deficit	(23,638,461)	(16,571,505)
Total stockholder's deficit	(3,792,806)	(164,094)
Non-controlling interest	(2,827,294)	(2,797,611)
Total stockholders' deficit	(6,620,100)	(2,961,705)
Total liabilities and stockholders' deficit	167,118	1,269,676
Series A Preferred Stock [Member]
Stockholders' deficit
Preferred stock, value	8	8
Series B Preferred Stock [Member]
Stockholders' deficit
Preferred stock, value	$ 10	$ 10

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2023	Jun. 30, 2022
Stockholders' deficit
Common stock, shares par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	5,000,000,000	5,000,000,000
Common stock, shares issued	389,433,144	365,239,001
Common stock, shares outstanding	389,433,144	365,239,001
Series A Preferred Shares [Member]
Stockholders' deficit
Preferred stock, shares par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares designated	3,500,000	3,500,000
Preferred stock, shares issued	757,395	781,132
Preferred stock, shares outstanding	757,395	781,132
Series B Preferred Shares [Member]
Stockholders' deficit
Preferred stock, shares par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares designated	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Consulting and advisory fees	$ 1,101,573	$ 3,031,959
Related party consulting fees	353,000	432,425
General and administrative expenses	302,693	1,184,654
Professional fees	271,021	444,012
Advertising and marketing expense	23,348	651,567
Research and development expense	0	5,267,581
Total operating expenses	2,051,635	11,012,198
Loss from operations	(2,051,635)	(11,012,198)
Other expenses:
Amortization of debt discount	(461,842)	(4,629,089)
Financing fees	0	(43,750)
Interest expense	(10,566)	(138,944)
Change in fair value of convertible bridge loans	(57,368)	0
Loss on impairment of investment	(156,460)	0
Loss from Ebenberg JV	(98,781)	(57,678)
Loss on extinguishment of debt	(4,259,987)	(536)
Total other expense	(5,045,004)	(4,869,997)
Net loss	(7,096,639)	(15,882,195)
Less net loss attributable to noncontrolling interest	(29,683)	(2,580,925)
Net income attributable to common stockholders	$ (7,066,956)	$ (13,301,270)
Net loss per common share - basic and diluted	$ (0.02)	$ (0.04)
Weighted average number of common shares outstanding - basic and diluted	375,098,691	345,160,167

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT - USD ($)	Total	Series A Preferred Stocks [Member]	Series B, Preferred Stock	Common Stock	Additional Paid-In Capital	Common Stock To Be Issued	Accumulated Deficit	Noncontrolling Interest
Balance, shares at Jun. 30, 2021		788,270	1,000,000	293,815,960
Balance, amount at Jun. 30, 2021	$ 705,306	$ 8	$ 10	$ 2,938	$ 4,138,181	$ 51,090	$ (3,270,235)	$ (216,686)
Sale of common stock, shares				39,366,666
Sale of common stock, amount	2,078,501	0	0	$ 394	2,166,057	(87,950)	0	0
Shares issued as equity kicker, shares				250,000
Shares issued as equity kicker, amount	43,750	0	0	$ 3	43,747	0	0	0
Exercise of warrants, shares				4,308,600
Exercise of warrants, amount	128,550	$ 0	0	$ 43	128,507	0	0	0
Conversion of Series A Preferred to Common Stock, shares		(7,138)		7,138,000
Conversion of Series A Preferred to Common Stock, amount	0	$ 0	0	$ 71	(71)	0	0	0
Conversion of convertible notes and accrued interest, shares				14,828,224
Conversion of convertible notes and accrued interest, amount	426,819	0	0	$ 148	429,761	(3,090)	0	0
Inducement of conversion-- interest expense, shares				845,936
Inducement of conversion-- interest expense, amount	134,929	0	0	$ 8	134,921	0	0	0
Stock issued for services, shares				4,685,615
Stock issued for services, amount	761,954	0	0	$ 47	670,007	91,900	0	0
Stock option compensation	3,248,181	0	0	0	3,248,181	0	0	0
Beneficial conversion feature associated with convertible debt	2,615,419	0	0	0	2,615,419	0	0	0
Warrants associated with convertible debt	2,777,081	0	0	0	2,777,081	0	0	0
Net loss	(15,882,195)	$ 0	$ 0	$ 0	0	0	(13,301,270)	(2,580,925)
Balance, shares at Jun. 30, 2022		781,132	1,000,000	365,239,001
Balance, amount at Jun. 30, 2022	(2,961,705)	$ 8	$ 10	$ 3,652	16,351,791	51,950	(16,571,505)	(2,797,611)
Conversion of Series A Preferred to Common Stock, shares		(23,737)		23,737,000
Conversion of Series A Preferred to Common Stock, amount	0	$ 0	0	$ 237	(237)	0		0
Stock issued for services, shares				457,143
Stock issued for services, amount	48,000	0	0	$ 5	47,995	0	0	0
Stock option compensation	702,116	0	0	0	702,116	0	0	0
Warrants associated with convertible debt	2,688,128	0	0	0	2,688,128	0	0	0
Net loss	(7,096,639)	$ 0	$ 0	$ 0	0	0	(7,096,956)	(29,683)
Balance, shares at Jun. 30, 2023		757,395	1,000,000	389,433,144
Balance, amount at Jun. 30, 2023	$ (6,620,100)	$ 8	$ 10	$ 3,894	$ 19,789,793	$ 51,950	$ (23,638,461)	$ (2,827,294)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Cash Flows from Operating Activities
Net Loss	$ (7,096,639)	$ (15,882,195)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	1,469	15,581
Stock option expense	702,116	3,248,181
Stock issued for services	48,000	761,954
Financing fees	0	43,750
Inducement of conversion of debt	0	134,929
Change in fair value of convertible bridge loans	57,368	0
Loss on extinguishment of debt	4,259,987	0
Loss from Ebenberg JV	98,781	57,678
Loss on impairment of investment	156,460	0
Amortization of debt discount	461,842	4,629,089
Amortization of right of use asset	45,431	40,867
Changes in operating assets and liabilities:
Prepaids	(3,763)	480
Accounts payable and accrued liabilities	145,722	(7,120)
Accrued liability, related party	(2,000)	(3,000)
Shares to be issued	0	75,200
Lease liabilities	(48,964)	(42,643)
Net cash from operating activities	(1,174,190)	(6,927,249)
Cash Flows from Investing Activities
Investment in JV Movychem	(197,563)	(115,356)
Purchase of property and equipment	(2,567)	(19,990)
Net cash from Investing activitie	(200,130)	(135,346)
Cash Flows from Financing Activities
Sale of common stock	0	2,078,500
Cash from exercise of warrants	0	128,550
Proceeds from convertible notes payable	0	4,958,950
Proceeds from convertible bridge loans	370,000	0
Net cash from financing activities	370,000	7,166,000
Net change in cash	(1,004,320)	103,405
Cash at beginning of period	1,065,945	962,540
Cash at end of period	61,625	1,065,945
Supplemental Cash Flow Information
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Conversion of convertible notes payable and accrued interest	0	426,819
Warrants issued with convertible notes payable	2,688,128	2,777,081
Beneficial conversion feature arising from convertible notes payable	$ 0	$ 2,615,419

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	12 Months Ended
ORGANIZATION AND NATURE OF BUSINESS	Jun. 30, 2023
ORGANIZATION AND NATURE OF BUSINESS
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Overview Xeriant, Inc. (the “Company”) is dedicated to the discovery, development and commercialization of advanced materials and technology related to next generation air and spacecraft, which can be successfully integrated and commercialized for deployment across multiple industrial sectors. The Company seeks to partner with and acquire strategic interests in visionary companies that accelerate this mission. Xeriant’s advanced materials line is marketed under the DUREVER™ brand, and includes NexBoard™, an eco-friendly, patent-pending composite building panel made from plastic and cellulose waste, designed to replace products such as drywall, plywood, OSB, MDF, MgO board and other materials used in construction. Operating History The Company is a development-stage enterprise with a limited operating history with no sales, and operating losses since its inception. The Company has had two joint ventures, one in the area of aerospace that was effective May 27, 2021, and the other involving advanced materials that was effective April 2, 2022, and terminated June 30, 2023. Advanced Materials A primary focus of the Company is the acquisition and commercial exploitation of eco-friendly, advanced materials and chemicals which have applications across a broad range of industries and the potential to generate significant near-term revenue. The Company’s commercialization strategy encompasses licensing arrangements and joint ventures, which would allow for more rapid access to the market with reduced capital requirements and financial risk. In addition to providing the production and distribution infrastructure, these established partnering companies can streamline testing and certification and add brand recognition value. The advanced materials and chemicals may be sold as standalone products, enhancements to existing products, or used in the development of proprietary products under a new trademarked brand owned by the Company. The Company is exploring manufacturing and branding opportunities for specific products derived from advanced materials and chemicals acquired or developed, which would involve setting up production facilities, equipment, systems and supply chain. Effective April 2, 2022, the Company entered into a Joint Venture Agreement with Movychem s.r.o, a Slovakian chemical ® On June 8, 2022, Xeriant announced the development of a multi-purpose, high-strength fire- and water-resistant composite panel made from a formulation of Retacell ® After experiencing a number of issues, including but not limited to Movychem’s unwillingness to provide material documentation, processes and information required for the exploitation of Retacell ® ® On July 11, 2023, Xeriant announced the successful testing of a proprietary high-volume production process for an environmentally friendly patent-pending composite construction panel (NexBoard”) that can be produced in the United States at industrial scale. This approach will enable the Company to unlock existing demand indicated by several homebuilders and developers seeking environmentally friendly construction panels in varying thicknesses and sizes, including standard 48” x 96” sheets, economically and with consistency and efficiency. On August 12, 2022, the Company filed the trademark “NexBoard,” for construction panels, namely, composite sheets and panels composed primarily of plastic, reinforcement materials and fire-retardant chemicals for use in walls, ceilings, flooring, framing, siding, roofing and decking. The trademark filing was intentionally broad and based upon demand for a general all-purpose construction panel made from a mixture of fire-retardant and recycled materials. Because of Movychem’s non-performance, as described above, Xeriant ceased paying Movychem $25,000 per month as required in the Joint Venture beginning December 2022. On February 13, 2023, Movychem formally requested dissolution of its Joint Venture with Xeriant, Ebenberg, LLC. On February 24, 2023, Xeriant provided a formal response to Movychem, highlighting its multiple and sustained lapses in collaborative efforts related to the commercialization of the Retacell ® ® ® On March 31, 2023, the Company filed a provisional patent application titled “Multilayered Fire-Resistant Polymer Composite and Method for Producing Same,” for a method of producing a unique fire-resistant thermoplastic and fiber composite material which may be formed or shaped into various construction products of different thicknesses and dimensions. This green material will be composed primarily of recycled plastic, cellulose and ecofriendly fire-retardant chemicals, including but not limited to use in walls, ceilings, flooring, framing, siding, roofing, molding, and decking, used in construction. Subject to available capital, the Company is planning to build manufacturing facilities in the United States for the production of NexBoard in order to meet market demand, or alternatively license the technology and process. The Company has identified potential sites for near-term contract manufacturing, a pilot plant, and larger manufacturing facilities, received bids for specialized manufacturing equipment, developed timetables related to the action plan, and hired a managing director with decades of experience to oversee the projects. Aerospace Another area of interest for the Company is the emerging aviation market called Advanced Air Mobility (AAM), the transition to more efficient, eco-friendly, automated and convenient flight operations enabled by the convergence of technological advancements in design and engineering, composite materials, propulsion systems, battery energy density and manufacturing processes. Next-generation aircraft being developed for this market offer low-cost, on-demand flight for passengers and cargo, utilizing lower altitude airspace and bypassing the traditional hub and spoke airport network with vertical takeoff and landing (VTOL) capabilities. Many of these lightweight aircraft are electrically powered through either hybrid or pure battery systems, which allows for quieter, low emission flights over urban areas, however with limited speed and range. The adoption and integration of niche aerial services through AAM is expected to provide benefits throughout the economy. The Company plans to partner with and acquire strategic interests in visionary companies that accelerate our mission of commercializing critical breakthrough AAM technologies which enhance performance, increase safety, and enable and support more efficient, autonomous, and sustainable flight operations, including electric and hybrid-electric passenger and cargo transport aircraft capable of vertical takeoff and landing. The Company’s plan to source and acquire strategic interests in leading aerospace companies developing breakthrough VTOL aircraft began in the second quarter of fiscal year 2021. Effective May 27, 2021, the Company entered into a Joint Venture Agreement with XTI Aircraft Company (“XTI”), a privately owned OEM based in Englewood, Colorado for the purpose of completing the preliminary design of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric vertical takeoff and landing (eVTOL) fixed-wing aircraft. Through the joint venture with XTI, (referred to hereinafter as the “XTI JV”), the Company was involved in the successful completion of the preliminary design of the TriFan 600 eVTOL aircraft. The TriFan 600 is being designed to become the fastest, longest-range VTOL aircraft in the world and the first commercial fixed-wing VTOL airplane, with current pre-orders of approximately $7 billion in gross revenue upon delivery of those aircraft. The purpose of the XTI JV, preliminary design review (PDR), had been achieved during the first quarter of fiscal year 2022. At that point, Xeriant had funded approximately $5.5 million into the XTI JV. On May 17, 2022, Xeriant signed a Letter Agreement with XTI related to the introduction of XTI to Inpixon, a Nasdaq-listed company. Under this Letter Agreement, if there was a combination or other transaction between XTI and Inpixon, Xeriant would receive compensation of 6 percent of XTI fully diluted pre-merger shares, and XTI would assume the obligations of Xeriant’s Senior Secured Note with Auctus Fund, LLC. On July 25, 2023, Inpixon filed an 8-K, announcing their intention to merge with XTI having executed an Agreement of Plan and Merger with XTI. The filing also showed that XTI had engaged in a transaction with Inpixon on March 10, 2023, receiving $300,000 in funding. Inpixon subsequently filed an S-4/A registration statement on October 6, 2023. In the area of aerospace, management believes that Xeriant can grow expeditiously by acquiring technology and assets primarily through acquisitions, joint ventures, strategic investments, and licensing arrangements. As a publicly traded company, the Company offers its subsidiaries such benefits as improved access to capital, higher valuations and lower risk through the shared ownership of a diversified portfolio, while allowing these entities to maintain independence in their distinct operations to focus on their fields of expertise. Cost savings and efficiencies may be realized from sharing non-operational functions such as finance, legal, tax, sales & marketing, human resources, purchasing power, as well as investor and public relations.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Jun. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC, and Eco-Aero, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP). All significant intercompany balances and transactions have been eliminated. The consolidated financial statements, which include the accounts of the Company and its subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The financial statements have been prepared using the accrual basis of accounting in accordance with U.S. GAAP and presented in US dollars. The fiscal year end is June 30. Going Concern These consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred net losses since inception and has an accumulated deficit of $23,638,461 as of June 30, 2023. During the year ended June 30, 2023, the Company’s net loss was $7,096,639 and at June 30, 2023, the Company had a working capital deficit of $6,684,867. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Based on its historical rate of expenditures, the Company expects to expend its available cash in approximately two months from October 12, 2023. Management’s plans include raising capital through the issuance of common stock and debt to fund operations and, eventually, the generation of revenue through its business. The Company does not expect to generate any significant revenue the foreseeable future. The Company is in immediate need of further working capital and is seeking options, with respect to financing, in the form of debt, equity or a combination thereof. Failure to raise adequate capital and generate adequate revenues could result in the Company having to curtail or cease operations. The Company’s ability to raise additional capital through the future issuances of the common stock is unknown. Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable it to develop to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern; however, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern. Principles of Consolidation The consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC (“AAT”), and Eco-Aero, LLC. The Company owns a 64% controlling interest of AAT; and a 50% interest in Eco-Aero, LLC, with control exercised through a majority membership in the management committee. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates. Fair Value Measurements and Fair Value of Financial Instruments The Company adopted Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3: Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements. ASC subtopic 825-10, Financial Instruments The Company follows ASC subtopic 820-10, Fair Value Measurements and Disclosures Cash and Cash Equivalents For the purposes of the consolidated statements of cash flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents. Impairment of Long-Lived Assets In accordance with ASC 360-10, Impairment and Disposal of Long Lived Asset Convertible Debentures The Company adopted the guidance in Accounting Standards Updated (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The Company adopted ASU 2020-06 utilizing the modified retrospective method, which resulted in an immaterial impact to the Company. Prior to adoption of ASU 2020-06, if the conversion features of conventional convertible debt provided for a rate of conversion that is below market value at issuance, this feature was characterized as a beneficial conversion feature ("BCF"). A BCF was recorded by the Company as a debt discount pursuant to ASC Topic 470-20 "Debt with Conversion and Other Options." In those circumstances, the convertible debt was recorded net of the discount related to the BCF, and the Company amortized the discount to interest expense, over the life of the debt. During the year ended June 30, 2022, the Company recorded a BCF in the amount of $2,615,419. Stock-based Compensation The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period. During the years ended June 30, 2023 and 2022, the Company recognized $702,116 and $3,248,181 in stock-based compensation expense, respectively. Leases The Company accounts for leases under ASU 2016-02. At the inception of a contract the Company assesses whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease right of use (“ROU”) assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is presented in operating expenses on the unaudited condensed consolidated statements of operations. Finance leases are recorded as a finance lease liability and property, plant and equipment asset, based on the present value of lease payments. The asset is depreciated, and the liability is amortized with interest expense incurred over the life of the lease. As permitted under the new guidance, the Company has made an accounting policy election not to apply the recognition provisions of the guidance to short term leases (leases with a lease term of twelve months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, the Company will recognize the lease payments for short term leases on a straight-line basis over the lease term. Investments The Company follows ASC 325-20, Cost Method Investments Research and Development Expenses Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $0 and $5,267,581 for the years ended June 30, 2023 and 2022, respectively. Advertising and Marketing Expenses The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $23,348 and $651,567 for the years ended June 30, 2023, and 2022, respectively. Income Taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company’s consolidated federal tax return and any state tax returns are not currently under examination. The Company follows ASC subtopic 740-10, Income Taxes Basic Income (Loss) Per Share Under the provisions of ASC 260, “ Earnings per Share Years ended June 30, 2023 2022 Warrants 104,802,161 55,512,161 Stock options 21,250,000 21,250,000 Convertible notes payable 62,283,909 50,968,829 Preferred stock 757,395,000 781,132,000 Total 945,731,070 908,862,990 Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB”) issued Accounting Standards Updated (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity On June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments

JOINT VENTURE

JOINT VENTURE	12 Months Ended
JOINT VENTURE	Jun. 30, 2023
JOINT VENTURE
JOINT VENTURE	NOTE 3 – JOINT VENTURE Joint Venture with XTI Aircraft On May 31, 2021, we entered into a Joint Venture Agreement (the “Agreement”) with XTI Aircraft Company (“XTI”), a Delaware corporation, to form the XTI JV, named Eco-Aero, LLC, with the purpose of completing the preliminary design review (“PDR”) of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric, eVTOL fixed wing aircraft. Under the Agreement, Xeriant is contributing capital, technology, and strategic business relationships, and XTI is contributing intellectual property licensing rights and know-how. XTI and the Company each own 50 percent of the XTI JV, and it is managed by a management committee consisting of five members, three appointed by Xeriant and two by XTI. The Agreement was effective on May 27, 2021, with an initial deposit of $1 million into the XTI JV. The Company’s financial commitment is up to $10 million, contributed as needed to complete the preliminary design of the aircraft. XTI completed Preliminary Design Review during the first quarter of fiscal year 2022, which was the purpose of the XTI JV. On May 17, 2022, we executed a confidential Letter Agreement with XTI, the material terms of which are briefly delineated as follows: • Xeriant would be entitled to compensation for its role in introducing XTI to Inpixon, a Nasdaq-listed company, contingent upon the occurrence of any merger, combination, or transactional event between XTI and the Nasdaq company. • XTI would assume the financial obligations related to the Senior Secured Note with Auctus Fund, LLC, including the $6.05 million principal balance of the note and warrant obligations. Additionally, Xeriant was to be granted a fully diluted equity interest amounting to 6% in XTI, issued immediately prior to any prospective combination with Inpixon. On June 5, 2023, after suspecting that the obligations under the Letter Agreement were possibly being evaded, the Company transmitted a formal demand letter to XTI requesting compliance with the provisions outlined in the Letter Agreement, and in accordance with section 8 of the JV Agreement with XTI. As of the date of this filing, we remain engaged in dialogue with XTI to enforce compliance with the Letter Agreement and to find an amicable resolution. The Company analyzed the transaction under ASC 810, Consolidation The Company includes the assets and liabilities related to the VIE in the consolidated balance sheets. Xeriant, Inc. provides cash to the VIE to fund its operations. The carrying amounts of consolidated VIE's assets and liabilities associated with the VIE subsidiary were as follows: June 30, 2023 June 30, 2022 Assets Cash $ - $ 4,516 Total Assets $ - $ 4,516 Liabilities Due from Xeriant Inc. $ 4,475,155 $ 4,479,547 Total Liabilities $ 4,475,155 $ 4,479,547 Joint Venture with Movychem On April 2, 2022, the Company entered into a Joint Venture Agreement with Movychem s.r.o., a Slovakian limited liability company, to exploit the Movychem Intellectual Property and the Purchased Patents. The Joint Venture is organized as a Florida limited liability company under the name Ebenberg, LLC, owned 50% by each of the Company and Movychem. For its capital contribution to the Joint Venture, pursuant to a Patent and Exclusive License and Assignment Agreement (the “Patent Agreement”), Movychem would transfer to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell® exclusive of all patents, and the Company would contribute the amount of $2,600,000 payable (a) $600,000 at the rate of $25,000 per month over a 24 month period and (b) $2,000,000 within five business days of a closing of a financing in which the Company receives net proceeds of at least $3,000,000 but in no event later than six months from the Effective Date. At such time as the Company makes a $2,000,000 payment (and assuming the Company is current with its then monthly capital contributions), pursuant to the Patent Agreement, Movychem would transfer all of its rights, title and interest to all of the patents related to Retacell for an amount equal to aggregate cash contributions of the Company to the Joint Venture plus 40% of all royalty payments received by the Joint Venture for the licensing of Retacell products. Pending assignment of the patents to the Joint Venture, pursuant to the Patent Agreement, Movychem would grant to the Joint Venture an exclusive worldwide license under the patents. Under the Joint Venture Agreement, the Company agreed to grant to certain individuals affiliated with Movychem five-year warrants (the “Warrants”) to purchase an aggregate of 170,000,000 shares of the Company’s common stock at an exercise price of $0.01 per share with vesting depending on the satisfaction of various milestones as described therein. of which none have yet to occur. The Company analyzed the transaction under ASC 810, Consolidation The Joint Venture Agreement granted to Movychem the right to dissolve the Joint Venture in the event that the Company fails to make any of its capital contributions in which case the Joint Venture will be required to grant back to Movychem all joint venture intellectual property and the assignment to Movychem of any outstanding licenses. After working with Movychem over the past year and experiencing a number of issues, including but not limited to Movychem’s unwillingness to provide material documentation, processes and information required for the exploitation of Retacell ® ® On August 12, 2022, the Company filed the trademark “NexBoard,” for construction panels, namely, composite sheets and panels composed primarily of plastic, reinforcement materials and fire-retardant chemicals for use in walls, ceilings, flooring, framing, siding, roofing and decking. The trademark filing was intentionally broad and based upon demand for a general all-purpose construction panel made from a mixture of fire-retardant and recycled materials. Because of Movychem’s non-performance as described above, Xeriant ceased paying Movychem $25,000 per month as provided in the Joint Venture beginning December 2022. On February 13, 2023, Movychem formally requested dissolution of its Joint Venture with Xeriant, named Ebenberg, LLC. On February 24, 2023, Xeriant provided a formal response to Movychem, highlighting its multiple and sustained lapses in collaborative efforts related to the commercialization of the Retacell technology. Subsequent to this communication, Xeriant expressly repudiated Movychem’s proposition for dissolution and their proposition to take an exclusive territory to market Retacell ® ® As of June 30, 2023 and 2022, the Company contributed $312,919 and $115,356 to the joint venture. During the year ended June 30, 2023, the Company fully impaired its investment in JV with Ebenberg LLC in the amount of $156,460.

CONCENTRATION OF CREDIT RISKS

CONCENTRATION OF CREDIT RISKS	12 Months Ended
CONCENTRATION OF CREDIT RISKS	Jun. 30, 2023
CONCENTRATION OF CREDIT RISKS
CONCENTRATION OF CREDIT RISKS	NOTE 4 – CONCENTRATION OF CREDIT RISKS The Company maintains accounts with financial institutions. All cash in checking accounts is non-interest bearing and is fully insured by the Federal Deposit Insurance Corporation (FDIC). At times, cash balances may exceed the maximum coverage provided by the FDIC on insured depositor accounts. The Company believes it mitigates its risk by depositing its cash and cash equivalents with major financial institutions. On June 30, 2023 and 2022, the Company had $0 and $811,429 in excess of FDIC insurance, respectively.

OPERATING LEASE RIGHT OF USE AS

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY	12 Months Ended
	Jun. 30, 2023
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
OPERATING LEASE RIGHT-OF-USE ASSET AND OPERATING LEASE LIABILITY	NOTE 5 – OPERATING LEASE RIGHT-OF-USE ASSET AND OPERATING LEASE LIABILITY The Company leases 2,911 square feet of office space located in the Research Park at Florida Atlantic University, Innovation Centre 1, 3998 FAU Boulevard, Suite 309, Boca Raton, Florida. The Company entered into a lease agreement commencing on November 1, 2019, through January 1, 2025, in which the first three months of rent were abated. Due to the COVID-19 pandemic, the Company decided to have all employees work from home and intends to build out the office space by the end of October 2023 to allow employees to work from the office beginning in November of 2023. The following table illustrates the base rent amounts over the term of the lease: Base Rent Periods November 1, 2019 to October 31, 2020 $ 4,367 November 1, 2020 to October 31, 2021 $ 4,498 November 1, 2021 to October 31, 2022 $ 4,633 November 1, 2022 to October 31, 2023 $ 4,772 November 1, 2023 to October 31, 2024 $ 4,915 November 1, 2024 to January 31, 2025 $ 5,063 Operating lease right-of-use asset and liability are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is the Company’s incremental borrowing rate, estimated to be 10%, as the interest rate implicit in most of the Company’s leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease term. Since the common area maintenance expenses are expenses that do not depend on an index or rate, they are excluded from the measurement of the lease liability and recognized in other general and administrative expenses on the consolidated statement of operations. During the years ended June 30, 2023 and 2022, the Company recorded $53,327 and $54,393 in rent expense, respectively in other general and administrative expenses on the consolidated statement of operations. Right-of-use asset is summarized below: June 30, 2023 June 30, 2022 Office lease $ 220,448 $ 220,448 Less accumulated amortization (137,537 ) (92,106 ) Right of use assets, net $ 82,911 $ 128,342 Operating lease liability is summarized below: June 30, 2023 June 30, 2022 Office lease $ 92,196 $ 141,160 Less: current portion (55,999 ) (48,963 ) Long term portion $ 36,197 $ 92,197 Maturity of lease liabilities are as follows: Year ended June 30, 2024 $ 62,201 Year ended June 30, 2025 37,112 Total future minimum lease payments 99,313 Less: Present value discount (7,117 ) Lease liability $ 92,196

CONVERTIBLE NOTES PAYABLE, IN D

CONVERTIBLE NOTES PAYABLE, IN DEFAULT	12 Months Ended
CONVERTIBLE NOTES PAYABLE, IN DEFAULT	Jun. 30, 2023
CONVERTIBLE NOTES PAYABLE, IN DEFAULT
CONVERTIBLE NOTES PAYABLE, IN DEFAULT	NOTE 6 – CONVERTIBLE NOTES PAYABLE, IN DEFAULT The carrying value of convertible notes payable, net of discount, as of June 30, 2023 and 2022, was $5,850,000 and $3,936,185, respectively. June 30, June 30, Convertible Notes Payable 2023 2022 Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC $ 5,850,000 $ 6,050,000 Total face value 5,850,000 6,050,000 Less unamortized discount - (2,113,815 ) Carrying value $ 5,850,000 $ 3,936,185 Auctus Fund LLC Senior Secured Note Through Maxim Group, LLC, Xeriant was introduced to Auctus Fund, LLC (“Auctus”) for the purpose of providing a bridge loan funding to satisfy the requirements of a pending merger with XTI Aircraft under a binding term sheet signed in September 2021. On October 27, 2021, the Company was issued a convertible note payable with Auctus Fund, LLC (the “Auctus Note”) with the principal of $6,050,000, consisting of $5,142,500, which was the actual amount funded, plus an original issue discount in the amount of $907,500 for interest on the unpaid principal amount at the rate of zero percent per annum from the issue date until the note becomes due and payable. The closing costs were $433,550, which included $308,550 in fees paid to Maxim and professional fees for completing the transaction. The Note had an initial due date of October 27, 2022. The Auctus Note provides the holder has the option to convert the principal balance to common stock of the Company at a conversion price of the lesser of (i) $0.1187 or (ii) 75% of the offering price per share divided by the number of shares of common stock. The Auctus Note is secured by the grant of a first priority security interest in the assets of the Company. In connection with the Auctus Note, the Company issued warrants indexed to an aggregate of 50,968,828 shares of common stock. The warrants have a term of five years and an exercise price of $0.1187. Effective August 1, 2022, the Company entered into an Amendment to the Senior Secured Promissory Note (the “First Amendment”) with Auctus pursuant to which the parties agreed to amend the Auctus Note. The Amendment (i) extended the maturity date of the Auctus Note to November 1, 2022, and (ii) extended the dates for the completion of the acquisition of XTI Aircraft and the uplist of the Company’s common stock to a national securities exchange to November 1, 2022. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 25,000,000 shares of common stock dated July 26, 2022 (the “Warrant”) at an exercise price of $0.09 per share and 5-year term; (ii) make a prepayment of the Note in the amount of $100,000; and (iii) cause a director of the Company to cancel his 10b-5(1) Plan. Effective December 27, 2022, the Company entered into a Second Amendment to the Senior Secured Promissory Note (the “Second Amendment”) with Auctus pursuant to which the parties agreed to further amend the Auctus Note. The Second Amendment (i) extended the maturity date of the Note, the obligation to uplist to a national securities exchange and acquisition of XTI Aircraft Company to March 15, 2023, and (ii) extended the date to file an S-1 registration statement to uplist the Company’s common stock to a national securities exchange to January 15, 2023. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 250,000,000 shares of Common Stock dated December 27, 2022 (the “New Warrant”) at an exercise price of $0.09 per share and 5-year term, and (ii) make two pre-payment installments of $50,000 on January 15, 2023, and February 15, 2023. As of June 30, 2023, a total of $50,000 remains outstanding and is recorded within accounts payable and accrued liabilities in the consolidated balance sheets. Since the Note was issued pre-adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The Company tested the first modification (“First Amendment”) under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification resulted in a loss on an extinguishment in the amount of $3,570,366 for the year ended June 30,2023. The loss on extinguishment was determined as follows: Reacquisition Price: Modified convertible debt instrument $ 5,950,000 Fair value of warrants 1,918,393 Cash payment 100,000 $ 7,968,393 Carrying Value of Original Instrument Original convertible debt instrument $ 6,050,000 Debt discount - warrant (707,585 ) Original issue discount (341,692 ) Debt discount - BCF (602,696 ) Carrying value of original debt 4,398,027 Loss on extinguishment $ 3,570,366 The Company tested the second modification (“Second Amendment”) under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification resulted in a loss on an extinguishment in the amount of $689,621. The loss on extinguishment was determined as follows: Reacquisition Price: Modified convertible debt instrument $ 5,850,000 Fair value of warrants 689,621 Accrued Short-term Liability 100,000 $ 6,639,621 Carrying Value of Original Instrument Carrying value of original debt 5,950,000 Loss on extinguishment $ 689,621 For the years ended June 30, 2023 and 2022, the Company recorded $461,842 and $4,369,735 in amortization of debt discount related to the Auctus note, respectively. As of June 30, 2023 and 2022, the carrying value of the Auctus note was $5,850,000 and $3,936,185, respectively.

CONVERTIBLE BRIDGE LOANS - AT F

CONVERTIBLE BRIDGE LOANS - AT FAIR VALUE	12 Months Ended
CONVERTIBLE BRIDGE LOANS - AT FAIR VALUE	Jun. 30, 2023
CONVERTIBLE BRIDGE LOANS - AT FAIR VALUE
CONVERTIBLE BRIDGE LOANS - AT FAIR VALUE	NOTE 7 – CONVERTIBLE BRIDGE LOANS – AT FAIR VALUE Between January 13, 2023, and March 31, 2023, the Company issued convertible bridge loans with an aggregate face value of $270,000. The notes have a coupon rate of 10% and a maturity date of one year. If the Company has a liquidity event (i.e. the Company a public offering of common stock (or units consisting of common stock and warrants to purchase common stock), resulting in the listing for trading of the common stock on the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange), the notes and any accrued interest automatically convert into common stock. The Liquidity Event Conversion Price is the lesser of (a) $0.09 and (b) the product of (x) the Liquidity Event Price multiplied by (z) 75%. In the event a liquidity event does not occur, the Holder has the option to convert the Notes on the maturity date at a conversion price of $0.09. In addition to the Notes, the holders received an aggregate 2,700,000 warrants. The warrants have an exercise price of $0.09 per share and have a five-year exercise term. The Company analyzed the Convertible Bridge Loans to determine if they were within the scope of ASC 480 Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity. The Company evaluated the detachable warrants under the requirements of ASC 480 and concluded that the warrants do not fall within the scope of ASC 480. The Company next evaluated the notes under the requirements of ASC 815 “ Derivatives and Hedging

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	12 Months Ended
CONVERTIBLE NOTES PAYABLE	Jun. 30, 2023
CONVERTIBLE NOTES PAYABLE
CONVERTIBLE NOTES PAYABLE	NOTE 8 – CONVERTIBLE NOTES PAYABLE Between May 13, 2023, and June 28, 2023, the Company issued convertible bridge loans with an aggregate face value of $100,000. The notes have a coupon rate of 10% and a maturity date of one year. The Notes are convertible at a fixed price of $0.01 per share. Since the Company adopted ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS	Jun. 30, 2023
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	NOTE 9 – FAIR VALUE MEASUREMENTS The following table presents the fair value hierarchy for the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2023 and 2022: June 30, 2023 June 30, 2022 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Assets Convertible Bridge Loans $ — $ — $ 247,254 $ — $ — $ — Fair values determined by Level 1 inputs utilize unadjusted quoted prices in active markets for identical assets. Level 3 instruments are characterized by unobservable inputs that are supported by little or no market activity, which require management judgment or estimation. The fair value of the Convertible Bridge Loans have three components: (i) principal, (ii) interest, and (iii) a redemption feature. The first two components (i.e. principal and interest) were valued using an income approach. For the Redemption Feature, the Company uses a Black-Scholes Merton (“BSM”) valuation technique because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving this component. Such assumptions include market price, strike price, term, market trading volatility and risk-free rates. Significant inputs and results arising from the BSM process are as follows for the redemption feature component of the Convertible Bridge Loans: Inception Dates Year Ended Quoted market price on valuation date $0.027 - $0.05 $ 0.024 Effective contractual conversion rates $0.09 - $0.012 $ 0.09 Contractual term to maturity 0.4 -1 year 0.25 – 0.75 year Market volatility: Volatility 115% - 135% 93.58% - 105.56% Risk-adjusted interest rate 4.32% - 5.14% 5.40% – 5.47% The following table summarizes the total carrying value of the Company’s Level 3 instruments held as of June 30, 2023, including cumulative unrealized gains and losses recognized during the years ended June 30, 2023 and 2022: Period Ended June 30, 2023 2022 Balances at beginning of period $ - $ - Issuances: Convertible Bridge Loans 189,886 - Changes in fair value inputs and assumptions reflected in income 57,368 - Balances at end of period $ 247,254 $ -

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
RELATED PARTY TRANSACTIONS	Jun. 30, 2023
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 10 – RELATED PARTY TRANSACTIONS Consulting fees During the years ended June 30, 2023 and 2022, the Company recorded $170,000 and $184,000 respectively, in consulting fees to Ancient Investments, LLC, a Company owned by the Company’s CEO, Keith Duffy and the Company’s Executive Director of Corporate Operations, Scott Duffy. As of June 30, 2023 and 2022, $10,000 and $15,000 was recorded in accrued liabilities respectfully. For the years ended June 30, 2023 and 2022, the Company recorded $102,000 and $122,000 respectively, in consulting fees to Edward DeFeudis, a Director of the Company. As of June 30, 2023 and 2022, $5,000 and $0 was recorded in accrued liabilities respectfully. During the years ended June 30, 2023 and 2022, the Company recorded $56,000 and $86,000 respectively, in consulting fees to AMP Web Services, a Company owned by the Company’s CTO, Pablo Lavigna. As of June 30, 2023, and 2022, $0 and $7,000 was recorded in accrued liabilities respectfully. During the years ended June 30, 2023 and 2022, the Company recorded $25,000 and $40,425 respectively, in consulting fees to Keystone Business Development Partners, a Company owned by the Company’s CFO, Brian Carey. As of June 30, 2023 and 2022, $5,000 and $0 was recorded in accrued liabilities respectfully.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2023
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 11 – COMMITMENTS AND CONTINGENCIES During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies Financial Advisory Agreements On August 10, 2021, the Company entered into an Advisory Agreement with an outside firm to assist the Company with fundraising activities. In connection with the agreement, the Company has the following commitments: · Issue 500,000 shares payable at the date of the agreement, 500,000 shares payable three months from the date of the agreement, 500,000 shares payable nine months from the date of the agreement. · Pay a financing fee of 1.5% of gross proceeds received by the Company up to $100,000,000; a financing fee of 1.25% of gross proceeds received by the Company from $100,000,000-$200,000,000, and a financing fee of 1% of gross proceeds received by the Company over $200,000,000. · M&A fee of 1.5% of the value of a business or asset sold up to $50,000,000; an M&A fee of 1.25% of value of a business or asset sold from $50,000,000-$100,000,000, an M&A fee of 1% of value of a business or asset sold from $100,000,000-$200,000,000, and an M&A fee of 0.5% of value of a business or asset sold over $200,000,000. During the year ended June 30, 2022, the Company issued all 1,500,000 shares under the agreement. On August 19, 2021, the Company entered into an Advisory Agreement with an outside firm to assist the Company with fundraising activities. In connection with the agreement, the Company has the following commitments: · Issue 2,225,000 common shares payable at the date of the agreement, and 2,225,000 common shares payable upon an uplisting of the Company’s common stock to a national exchange. · Pay a cash fee of seven percent 7% of the amount of capital raised, invested or committed; and deliver a warrant (the “Agent Warrant”) to purchase shares of the common stock equal to seven percent (7%) of the number of shares of common stock underlying the securities issued in the Financing. · Pay a cash fee for entering into a transaction including, without limitation, a merger, acquisition or sale of stock or assets equal to one- and one-half percent (1.5%), or in the event a transaction is consummated with a party that was in communication with the Company prior to the date of this contract, then the fee shall equal one half percent (0.5%). During the year ended June 30, 2022, the Company issued the initial 2,225,000 shares. There were no additional shares issued during the fiscal year ended June 30, 2023. Board of Advisors Agreements The Company has entered into Advisor Agreements with various advisory board members. The agreements provide for the following: On July 1, 2021, the Company agreed to issue 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, and for each of the following three years (beginning July 1, 2022), an option to purchase an additional 1,000,000 common shares per year thereafter at a 25% discount to the average market price for the preceding 10 trading days. The agreement also provides for a 1% finders fee. On July 6, 2021, provided an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 250,000 common shares issued upon a strategic partnership with a major airline, $2,500 per formal meeting paid in common shares, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. On July 28, 2021, the Company agreed to issue 250,000 common shares immediately, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 5,000,000 common shares for bringing in a strategic partner that significantly strengthens the Company’s market position, $2,500 per formal meeting paid in cash, common shares or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. The agreement also provides for a 30% commission. On August 9, 2021, the Company agreed to issue 50,000 common shares vesting over the first year, $2,500 per meeting paid in cash, common shares, or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. On August 20, 2021, the Company agreed to issue 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 4,000,000 common shares at $0.12 per share, vesting quarterly over 24 months. On March 1, 2022, the Company agreed to issue 150,000 common shares vesting monthly over one year, $2,500 per meeting paid in cash, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. On January 20, 2022, the Company agreed to issue 150,000 common shares vesting monthly over one year, and $2,500.00 per meeting paid in cash and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. On March 20, 2022, the Company agreed to issue 150,000 common shares vesting monthly over one year, and $2,500.00 per meeting paid in cash and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. There were no additional Advisory Agreements executed during the fiscal year ended June 30, 2023.

EQUITY

EQUITY	12 Months Ended
EQUITY	Jun. 30, 2023
EQUITY
EQUITY	NOTE 12 – EQUITY Common Stock As of June 30, 2023 and 2022, the Company had 5,000,000,000 shares of common stock authorized with a par value of $0.00001. There were 389,433,144 and 365,239,001 shares issued and outstanding as of June 30, 2023 and 2022, respectively. Fiscal Year 2022 Issuances During the year ended June 30, 2022, in connection with one of the subscription agreements, the Company issued 250,000 shares as an equity kicker valued at $43,753, which has been expensed as financing costs. During the year ended June 30, 2022, the Company issued 4,308,600 shares of common stock as a result of warrant exercises in the aggregate proceeds of $128,550. During the year ended June 30, 2022, the Company issued 4,685,615 shares of common stock for services, valued at $761,954. During the year ended June 30, 2022, the Company sold 39,366,666 shares of common stock for aggregate proceeds of $2,078,501. During the year ended June 30, 2022, the Company issued 7,138,000 shares of common stock in exchange for the conversion of 7,138 shares of Series A Preferred Stock. During the year ended June 30, 2022, the Company issued 10,598,544 shares of common stock for the conversion of $167,550 in principal and $4,984 in accrued interest. This resulted in a loss on extinguishment of debt in the amount of $536. During the year ended June 30, 2022, the Company issued 4,229,680 shares of common stock for the conversion of $250,000 principal balance of convertible notes payable and $3,749 accrued interest. During the year ended June 30, 2022, the Company issued 845,936 shares of common stock in exchange for the inducement to the convertible notes holders to convert at fair value of $134,929. Fiscal Year 2023 Issuances During the year ended June 30, 2023, the Company issued 1,000,000 shares of common stock in exchange for the conversion of 1,000 shares of Series A Preferred Stock. During the year ended June 30, 2023, the Company issued 457,143 shares to a consultant for services valued at $48,000. During the year ended June 30, 2023, the Company issued 10,237,000 shares of common stock in exchange for the conversion of 10,237 shares of Series A preferred stock. During the year ended June 30, 2023, the Company issued 5,000,000 shares of common stock in exchange for the conversion of 500 shares of Series A preferred stock. During the year ended June 30, 2023, the Company issued 7,500,000 shares of common stock in exchange for the conversion of 7,500 shares of Series A preferred stock. Series A Preferred Stock There are 100,000,000 shares authorized as preferred stock, of which 3,500,000 are designated as Series A preferred stock having a par value of $0.00001 per share. The Series A preferred stock has the following rights: · Voting · Dividends · Conversion · The shares of Series A Preferred Stock are redeemable at the option of the Corporation at any time after September 30, 2022 upon not less than 30 days written notice to the holders. It is not mandatorily redeemable. As of June 30, 2023 and 2022, the Company had 757,395 and 781,132 shares of Series A preferred stock issued and outstanding, respectively. On July 11, 2022, the Company issued 1,000,000 shares of common stock in exchange for the conversion of 1,000 shares of Series A preferred stock. On October 24, 2022, the Company issued 10,237,000 shares of common stock in exchange for the conversion of 10,237 shares of Series A preferred stock. On March 17, 2023, the Company issued 5,000,000 shares of common stock in exchange for the conversion of 5,000 shares of Series A preferred stock. On May 26, 2023, the Company issued 7,500,000 shares of common stock in exchange for the conversion of 7,500 shares of Series A preferred stock. Series B Preferred Stock On March 25, 2021, the Certificate of Designation for the Series B Preferred was recorded by the State of Nevada. There are 100,000,000 shares authorized as preferred stock, of which 1,000,000 are designated as Series B Preferred Stock having a par value of $0.00001 per share. The Series B preferred stock is not convertible, grants 5,000 votes and no liquidation preference. Stock Options In connection with certain advisory board compensation agreements, the Company issued an aggregate 21,250,000 options at an exercise price of $0.12 per share for the year ended June 30, 2022. These options vest quarterly over twenty-four months and have a term of three years. The grant date fair value was $3,964,207. The Company recorded compensation expense in the amount of $702,116 and $3,248,181 for these options for the years ended June 30, 2023 and 2022, respectively. As of June 30, 2023, there was $0 of total unrecognized compensation cost related to non-vested portion of options granted. As of June 30, 2023, there are 21,250,000 options outstanding, of which 20,687,500 are exercisable. The weighted average remaining term is 1.11 years. A summary of the Company’s stock options activity is as follows: Number of Options Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2021 - - Granted 21,250,000 $ 0.12 Exercised - - Canceled - - Outstanding at June 30, 2022 21,250,000 $ 0.12 2.1 Granted - Exercised - - Canceled - - Outstanding at June 30, 2023 21,250,000 $ 0.12 1.11 $ - Exercisable at June 30, 2023 20,687,500 $ 0.12 1.11 $ - Significant inputs and results arising from the Black-Scholes process are as follows for the options: Quoted market price on valuation date $0.169 - $0.23 Exercise prices $0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility: Range of equivalent volatility 181.21% - 275.73% Range of interest rates 0.20% - 1.08% Warrants As of June 30, 2023, and 2022, the Company had 104,802,161 and 55,512,161 warrants outstanding, respectively. The warrants have a term of two to five years and an exercise price range from $0.021 and $0.1187. The Company evaluated the warrants under ASC 815, Derivatives and Hedging As of June 30, 2023 and 2022, the Company had 104,802,161 and 55,512,161 warrants outstanding respectively. The warrants are detailed as follows: Number of Warrants Number of Warrants Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2021 8,848,333 $ 0.0300 0.94 $ - Granted 50,968,828 $ 0.1187 4.6 $ - Exercised (4,305,000 ) Canceled - Outstanding at June 30, 2022 55,512,161 $ 0.1110 Granted 52,700,000 $ 0.0865 5.003 Exercised - Canceled (3,410,000 ) Outstanding at June 30, 2023 104,802,161 $ 0.1015 3.791 $ - Vested and expected to vest at June 30, 2023 104,802,161 $ 0.1015 3.7905 $ - Exercisable at June 30, 2023 104,802,161 $ 0.1015 3.7905 $ -

NONCONTROLLING INTEREST

NONCONTROLLING INTEREST	12 Months Ended
NONCONTROLLING INTEREST	Jun. 30, 2023
NONCONTROLLING INTEREST
NON-CONTROLLING INTEREST	NOTE 13 - NON-CONTROLLING INTEREST None

INCOME TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Jun. 30, 2023
INCOME TAXES
INCOME TAXES	NOTE 14 – INCOME TAXES The Company accounts for income taxes in accordance with the provisions of FASB ASC 740, Accounting for Uncertainty in Income Taxes. At June 30, 2023 and 2022, the significant components of the deferred tax assets are summarized below: June 30, June 30, 2023 2022 Net operating loss carry-forward $ 7,460,414 $ 5,860,409 Valuation Allowance (7,460,414 ) (5,860,409 ) Net Deferred Tax Asset (Liability) $ - $ - The Company periodically evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carryforward periods available to the Company for tax reporting purposes, and other relevant factors. Future changes in the unrecognized tax benefit will have no impact on the effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change significantly within the next twelve months. The Company will continue to classify income tax penalties and interest as part of general and administrative expenses in its consolidated statements of operations. There were no interest or penalties accrued as of June 30, 2023.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2023
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS On August 7, 2023, the Company established a wholly owned subsidiary, BlueGreen Composites, LLC, to better manage the business operations of the green building products business line. As of the date of this filing, no bank account was opened, no contracts or agreements were executed, and no business operations were undertaken. On July 30, 2023, we filed the trademark BlueGreen for ecofriendly composite building products and “Durever” for the same categories on July 31, 2023. From July 1, 2023, through October 12, 2023, a total of $461,000 in convertible notes were issued.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Jun. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	The consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC, and Eco-Aero, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP). All significant intercompany balances and transactions have been eliminated. The consolidated financial statements, which include the accounts of the Company and its subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The financial statements have been prepared using the accrual basis of accounting in accordance with U.S. GAAP and presented in US dollars. The fiscal year end is June 30.
Going Concern	These consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred net losses since inception and has an accumulated deficit of $23,638,461 as of June 30, 2023. During the year ended June 30, 2023, the Company’s net loss was $7,096,639 and at June 30, 2023, the Company had a working capital deficit of $6,684,867. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Based on its historical rate of expenditures, the Company expects to expend its available cash in approximately two months from October 12, 2023. Management’s plans include raising capital through the issuance of common stock and debt to fund operations and, eventually, the generation of revenue through its business. The Company does not expect to generate any significant revenue the foreseeable future. The Company is in immediate need of further working capital and is seeking options, with respect to financing, in the form of debt, equity or a combination thereof. Failure to raise adequate capital and generate adequate revenues could result in the Company having to curtail or cease operations. The Company’s ability to raise additional capital through the future issuances of the common stock is unknown. Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable it to develop to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern; however, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Principles of Consolidation	The consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC (“AAT”), and Eco-Aero, LLC. The Company owns a 64% controlling interest of AAT; and a 50% interest in Eco-Aero, LLC, with control exercised through a majority membership in the management committee. All significant intercompany balances and transactions have been eliminated.
Use of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.
Fair Value Measurements and Fair Value of Financial Instruments	The Company adopted Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3: Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements. ASC subtopic 825-10, Financial Instruments The Company follows ASC subtopic 820-10, Fair Value Measurements and Disclosures
Cash and Cash Equivalents	For the purposes of the consolidated statements of cash flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents.
Impairment of Long-Lived Assets	In accordance with ASC 360-10, Impairment and Disposal of Long Lived Asset
Convertible Debentures	The Company adopted the guidance in Accounting Standards Updated (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The Company adopted ASU 2020-06 utilizing the modified retrospective method, which resulted in an immaterial impact to the Company. Prior to adoption of ASU 2020-06, if the conversion features of conventional convertible debt provided for a rate of conversion that is below market value at issuance, this feature was characterized as a beneficial conversion feature ("BCF"). A BCF was recorded by the Company as a debt discount pursuant to ASC Topic 470-20 "Debt with Conversion and Other Options." In those circumstances, the convertible debt was recorded net of the discount related to the BCF, and the Company amortized the discount to interest expense, over the life of the debt. During the year ended June 30, 2022, the Company recorded a BCF in the amount of $2,615,419.
Stock-based Compensation	The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period. During the years ended June 30, 2023 and 2022, the Company recognized $702,116 and $3,248,181 in stock-based compensation expense, respectively.
Leases	The Company accounts for leases under ASU 2016-02. At the inception of a contract the Company assesses whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease right of use (“ROU”) assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is presented in operating expenses on the unaudited condensed consolidated statements of operations. Finance leases are recorded as a finance lease liability and property, plant and equipment asset, based on the present value of lease payments. The asset is depreciated, and the liability is amortized with interest expense incurred over the life of the lease. As permitted under the new guidance, the Company has made an accounting policy election not to apply the recognition provisions of the guidance to short term leases (leases with a lease term of twelve months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, the Company will recognize the lease payments for short term leases on a straight-line basis over the lease term.
Investments	The Company follows ASC 325-20, Cost Method Investments
Research and Development Expenses	Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $0 and $5,267,581 for the years ended June 30, 2023 and 2022, respectively.
Advertising and Marketing Expenses	The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $23,348 and $651,567 for the years ended June 30, 2023, and 2022, respectively.
Income Taxes	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company’s consolidated federal tax return and any state tax returns are not currently under examination. The Company follows ASC subtopic 740-10, Income Taxes
Basic Income (Loss) Per Share	Under the provisions of ASC 260, “ Earnings per Share Years ended June 30, 2023 2022 Warrants 104,802,161 55,512,161 Stock options 21,250,000 21,250,000 Convertible notes payable 62,283,909 50,968,829 Preferred stock 757,395,000 781,132,000 Total 945,731,070 908,862,990
Recent Accounting Pronouncements	In August 2020, the Financial Accounting Standards Board (FASB”) issued Accounting Standards Updated (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity On June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Jun. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of potentially dilutive common securities	Years ended June 30, 2023 2022 Warrants 104,802,161 55,512,161 Stock options 21,250,000 21,250,000 Convertible notes payable 62,283,909 50,968,829 Preferred stock 757,395,000 781,132,000 Total 945,731,070 908,862,990

JOINT VENTURE (Tables)

JOINT VENTURE (Tables)	12 Months Ended
JOINT VENTURE (Tables)	Jun. 30, 2023
JOINT VENTURE
Schedule consolidated VIE's assets and liabilities associated with the VIE subsidiary	June 30, 2023 June 30, 2022 Assets Cash $ - $ 4,516 Total Assets $ - $ 4,516 Liabilities Due from Xeriant Inc. $ 4,475,155 $ 4,479,547 Total Liabilities $ 4,475,155 $ 4,479,547

OPERATING LEASE RIGHTOFUSE ASSE

OPERATING LEASE RIGHTOFUSE ASSET AND OPERATING LEASE LIABILITY (Tables)	12 Months Ended
	Jun. 30, 2023
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Schedule of rent periods	November 1, 2019 to October 31, 2020 $ 4,367 November 1, 2020 to October 31, 2021 $ 4,498 November 1, 2021 to October 31, 2022 $ 4,633 November 1, 2022 to October 31, 2023 $ 4,772 November 1, 2023 to October 31, 2024 $ 4,915 November 1, 2024 to January 31, 2025 $ 5,063
Summary of leases	June 30, 2023 June 30, 2022 Office lease $ 220,448 $ 220,448 Less accumulated amortization (137,537 ) (92,106 ) Right of use assets, net $ 82,911 $ 128,342 June 30, 2023 June 30, 2022 Office lease $ 92,196 $ 141,160 Less: current portion (55,999 ) (48,963 ) Long term portion $ 36,197 $ 92,197 Year ended June 30, 2024 $ 62,201 Year ended June 30, 2025 37,112 Total future minimum lease payments 99,313 Less: Present value discount (7,117 ) Lease liability $ 92,196

CONVERTIBLE NOTES PAYABLE, IN_2

CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Tables)	12 Months Ended
CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Tables)	Jun. 30, 2023
CONVERTIBLE NOTES PAYABLE, IN DEFAULT
Schedule of convertible notes payable	June 30, June 30, Convertible Notes Payable 2023 2022 Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC $ 5,850,000 $ 6,050,000 Total face value 5,850,000 6,050,000 Less unamortized discount - (2,113,815 ) Carrying value $ 5,850,000 $ 3,936,185
Schedule of loss on extinguishment of debt	Reacquisition Price: Modified convertible debt instrument $ 5,950,000 Fair value of warrants 1,918,393 Cash payment 100,000 $ 7,968,393 Carrying Value of Original Instrument Original convertible debt instrument $ 6,050,000 Debt discount - warrant (707,585 ) Original issue discount (341,692 ) Debt discount - BCF (602,696 ) Carrying value of original debt 4,398,027 Loss on extinguishment $ 3,570,366 Reacquisition Price: Modified convertible debt instrument $ 5,850,000 Fair value of warrants 689,621 Accrued Short-term Liability 100,000 $ 6,639,621 Carrying Value of Original Instrument Carrying value of original debt 5,950,000 Loss on extinguishment $ 689,621

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Jun. 30, 2023
FAIR VALUE MEASUREMENTS
Schedule of fair value of assets and liabilities	June 30, 2023 June 30, 2022 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Assets Convertible Bridge Loans $ — $ — $ 247,254 $ — $ — $ —
Schedule of convertible bridge loans	Inception Dates Year Ended Quoted market price on valuation date $0.027 - $0.05 $ 0.024 Effective contractual conversion rates $0.09 - $0.012 $ 0.09 Contractual term to maturity 0.4 -1 year 0.25 – 0.75 year Market volatility: Volatility 115% - 135% 93.58% - 105.56% Risk-adjusted interest rate 4.32% - 5.14% 5.40% – 5.47%
Schedule of unrealized gains and losses recognized	Period Ended June 30, 2023 2022 Balances at beginning of period $ - $ - Issuances: Convertible Bridge Loans 189,886 - Changes in fair value inputs and assumptions reflected in income 57,368 - Balances at end of period $ 247,254 $ -

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
EQUITY (Tables)	Jun. 30, 2023
EQUITY
Schedule of stock options activity	Number of Options Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2021 - - Granted 21,250,000 $ 0.12 Exercised - - Canceled - - Outstanding at June 30, 2022 21,250,000 $ 0.12 2.1 Granted - Exercised - - Canceled - - Outstanding at June 30, 2023 21,250,000 $ 0.12 1.11 $ - Exercisable at June 30, 2023 20,687,500 $ 0.12 1.11 $ -
Schedule of Black-Scholes process	Quoted market price on valuation date $0.169 - $0.23 Exercise prices $0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility: Range of equivalent volatility 181.21% - 275.73% Range of interest rates 0.20% - 1.08%
Schedule of stock warrants activity	Number of Warrants Number of Warrants Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2021 8,848,333 $ 0.0300 0.94 $ - Granted 50,968,828 $ 0.1187 4.6 $ - Exercised (4,305,000 ) Canceled - Outstanding at June 30, 2022 55,512,161 $ 0.1110 Granted 52,700,000 $ 0.0865 5.003 Exercised - Canceled (3,410,000 ) Outstanding at June 30, 2023 104,802,161 $ 0.1015 3.791 $ - Vested and expected to vest at June 30, 2023 104,802,161 $ 0.1015 3.7905 $ - Exercisable at June 30, 2023 104,802,161 $ 0.1015 3.7905 $ -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Jun. 30, 2023
INCOME TAXES
Schedule of components of deferred income tax assets	June 30, June 30, 2023 2022 Net operating loss carry-forward $ 7,460,414 $ 5,860,409 Valuation Allowance (7,460,414 ) (5,860,409 ) Net Deferred Tax Asset (Liability) $ - $ -

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Warrants	104,802,161	55,512,161
Stock options	21,250,000	21,250,000
Convertible notes payable	62,283,909	50,968,829
Preferred stock	757,395,000	781,132,000
Total	945,731,070	908,862,990

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Stock-based compensation expense	$ 702,116	$ 3,248,181
Research and development expenses	$ 0	5,267,581
Ownership percentage	64%
Accumulated deficit	$ (23,638,461)	(16,571,505)
Working capital	(6,684,867)
Net Loss	(7,096,639)	(15,882,195)
Advertising expenses	$ 23,348	651,567
Beneficial conversion feature		$ 2,615,419
Eco-Aero, LLC [Member]
Ownership percentage	50%
Ebenberg LLC [Member]
Impaired of investment	$ 156,460

JOINT VENTURE (Details)

JOINT VENTURE (Details) - VIE Unauited Condensed Consolidated Balance Sheet [Member] - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Cash	$ 0	$ 4,516
Total Assets	0	4,516
Due from Xeriant Inc.	4,475,155	4,479,547
Total Liabilities	$ 4,475,155	$ 4,479,547

JOINT VENTURE (Details Narrativ

JOINT VENTURE (Details Narrative) - USD ($)		1 Months Ended		12 Months Ended
JOINT VENTURE (Details Narrative) - USD ($)	Apr. 02, 2022	May 17, 2022	May 31, 2021	Jun. 30, 2023	Jun. 30, 2022
Description of Movychem's non-performance				Xeriant ceased paying Movychem $25,000 per month as provided in the Joint Venture beginning December 2022
Joint Venture With Movychem [Member]
Ownership owned percentage	50%
Contribution amount				$ 312,919	$ 115,356
Description about intellectual property	Movychem would transfer to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell® exclusive of all patents, and the Company would contribute the amount of $2,600,000 payable (a) $600,000 at the rate of $25,000 per month over a 24 month period and (b) $2,000,000 within five business days of a closing of a financing in which the Company receives net proceeds of at least $3,000,000 but in no event later than six months from the Effective Date
Company payment	$ 2,000,000
Purchase number of share common stock	170,000,000
Impairment of investment				$ 156,460
Exercise price	$ 0.01
Series A Preferred Stocks [Member]
Ownership owned percentage			50%
financial commitment agreegate amount			$ 10,000,000
Initial Deposit			1,000,000
Diluted equity interest		6%
Principal balance of the note and warrant		$ 6,050,000
Investment obligation			$ 10,000,000

CONCENTRATION OF CREDIT RISKS (

CONCENTRATION OF CREDIT RISKS (Details Narrative) - USD ($)	12 Months Ended
CONCENTRATION OF CREDIT RISKS (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
CONCENTRATION OF CREDIT RISKS
Cash in excess of FDIC insurance	$ 0	$ 811,429

OPERATING LEASE RIGHT OF USE _2

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details)	12 Months Ended
	Jun. 30, 2023 USD ($)
November 1, 2022 to October 31, 2023 [Member]
Base rent	$ 4,772
November 1 2020 to October 31 2021 [Member]
Base rent	4,498
November 1, 2021 to October 31, 2022 [Member]
Base rent	4,633
November 1 2023 to October 31 2024 [Member]
Base rent	4,915
November 1, 2024 to January 31, 2025 [Member]
Base rent	5,063
November 1, 2019 to October 31, 2020 [Member]
Base rent	$ 4,367

OPERATING LEASE RIGHT OF USE _3

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details 1) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Office lease	$ 220,448	$ 220,448
Less accumulated amortization	(137,537)	(92,106)
Right-of-use assets net	$ 82,911	$ 128,342

OPERATING LEASE RIGHT OF USE _4

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details 2) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Office lease	$ 92,196	$ 141,160
Less current portion	(55,999)	(48,963)
Long term portion	36,197	$ 92,197
Maturity of the lease liability is as follows
Year ended June 30, 2024	62,201
Year ended June 30, 2025	37,112
Total future minimum lease payments	99,313
Less: Present value discount	(7,117)
Lease liability	$ 92,196

OPERATING LEASE RIGHT OF USE _5

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Borrowing Interest Rate	10%
Other general and administrative expenses	$ 53,327	$ 54,393
Lease Agreement [Member]
Capital Leases Description	The Company leases 2,911 square feet of office space located in the Research Park at Florida Atlantic University, Innovation Centre 1, 3998 FAU Boulevard, Suite 309, Boca Raton, Florida

CONVERTIBLE NOTES PAYABLE, IN_3

CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Total face value	$ 5,850,000	$ 6,050,000
Less unamortized discount	0	(2,113,815)
Carrying value	5,850,000	3,936,185
Convertible notes payable issued October 27, 2021
Total face value	$ 5,850,000	$ 6,050,000

CONVERTIBLE NOTES PAYABLE, IN_4

CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Details 1)	12 Months Ended
CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Details 1)	Jun. 30, 2023 USD ($)
Reacquisition Price
Modified convertible debt instrument	$ 5,950,000
Fair value of warrants	1,918,393
Cash payment	100,000
Total	7,968,393
Carrying Value of Original Instrument
Original convertible debt instrument	6,050,000
Debt discount - warrant	(707,585)
Original issue discount	(341,692)
Debt discount - BCF	(602,696)
Carrying value of original debt	4,398,027
Loss on an extinguishment	$ 3,570,366

CONVERTIBLE NOTES PAYABLE, IN_5

CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Details 2)	12 Months Ended
CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Details 2)	Jun. 30, 2023 USD ($)
Reacquisition Price
Modified convertible debt instrument	$ 5,850,000
Fair value of warrants	689,621
Accrued Short-term Liability	100,000
Total	6,639,621
Carrying Value of Original Instrument
Carrying value of original debt	5,950,000
Loss on an extinguishment	$ 689,621

CONVERTIBLE NOTES PAYABLE, IN_6

CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Details Narrative) - USD ($)		1 Months Ended				12 Months Ended
	Jan. 15, 2023	Feb. 15, 2023	Dec. 27, 2022	Jul. 26, 2022	Oct. 27, 2021	Jun. 30, 2023	Jun. 30, 2022
Carrying value of convertible notes payable, net of discount						$ 5,850,000	$ 3,936,185
Accounts payable and accrued liabilities						50,000
Carrying value of Auctus note						5,850,000	3,936,185
Amortization of debt discount						461,842	4,369,735
Additional paid-in capital						2,365,419
Exercise price				$ 0.09
Professional fees						271,021	444,012
Loss on an extinguishment						(4,259,987)	$ (536)
First Amendment [Member]
Loss on an extinguishment						3,570,366
Second Amendment [Member]
Loss on an extinguishment						$ 689,621
Secured Debt [Memebr] \| Senior Secured Note [Member] \| Auctus Fund, LLC [Member]
Original issue discount					$ 907,500
Debt instrument converted principal amount					6,050,000
Purchase price					$ 5,142,500
Conversion price					$ 0.1187
Aggregate warrant issued of common stock					50,968,828
Exercise price					$ 0.1187
Professional fees					$ 433,550
Closing costs					$ 308,550
Secured Debt [Memebr] \| Promissory Note [Member] \| Auctus Fund, LLC [Member] \| October 27, 2021 [Member]
Exercise price			$ 0.09	$ 0.09
Maturity date			Mar. 15, 2023	Nov. 01, 2022
Term year			5 years	5 years
New warrant to purchase shares of Common Stock			250,000,000	25,000,000
Prepayment of the Note	$ 50,000	$ 50,000		$ 100,000

CONVERTIBLE BRIDGE LOANS AT FAI

CONVERTIBLE BRIDGE LOANS AT FAIR VALUE (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023	Jul. 26, 2022
Exercise price				$ 0.09
Interest expenses	$ 10,083	$ 0
Convertible notes payable, aggregate face value	$ 270,000	250,000
Between January 13, 2023 and March 31, 2023 [Member]
Exercise price	$ 0.09
New warrant to purchase shares of Common Stock	2,700,000
Interest expenses	$ 483
Conversion price	$ 0.09
Prepayment of the Note	$ 80,114
Fair value of Convertible Bridge Loans	57,368	$ 0
Convertible notes payable, aggregate face value	$ 247,254		$ 100,000	$ 0
Interest rate	10%		10%

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023	Jul. 26, 2022
Interest expenses	$ 10,083	$ 0
Convertible notes payable, aggregate face value	270,000	$ 250,000
Between January 13, 2023 and March 31, 2023 [Member]
Conversion price			$ 0.01
Interest expenses	483
Convertible notes payable, aggregate face value	$ 247,254		$ 100,000	$ 0
Interest rate	10%		10%

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Fair Value Inputs Level 2 [Member]
Convertible Bridge Loans	$ 0	$ 0
Fair Value Inputs Level 1 [Member]
Convertible Bridge Loans	0	0
Fair Value Inputs Level 3 [Member]
Convertible Bridge Loans	$ 247,254	$ 0

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details 1)	12 Months Ended
FAIR VALUE MEASUREMENTS (Details 1)	Jun. 30, 2023 $ / shares
Year Ended [Member]
Effective contractual conversion rates	$ 0.09
Quoted market price on valuation date	$ 0.024
Minimum [Member] \| Inception Dates [Member]
Risk-adjusted interest rate	4.32%
Effective contractual conversion rates	$ 0.09
Contractual term to maturity	4 months 24 days
Volatility	115%
Quoted market price on valuation date	$ 0.027
Minimum [Member] \| Year Ended [Member]
Risk-adjusted interest rate	5.40%
Contractual term to maturity	3 months
Volatility	93.58%
Maximum [Member] \| Inception Dates [Member]
Risk-adjusted interest rate	5.14%
Contractual term to maturity	1 year
Volatility	135%
Quoted market price on valuation date	$ 0.05
Effective contractual conversion rates	$ 0.012
Maximum [Member] \| Year Ended [Member]
Risk-adjusted interest rate	5.47%
Contractual term to maturity	9 months
Volatility	105.56%

FAIR VALUE MEASUREMENTS (Deta_3

FAIR VALUE MEASUREMENTS (Details 2)	12 Months Ended
FAIR VALUE MEASUREMENTS (Details 2)	Jun. 30, 2023 USD ($)
FAIR VALUE MEASUREMENTS
Balances at beginning of period	$ 0
Convertible Bridge Loans	189,886
Changes in fair value inputs and assumptions reflected in income	57,368
Balances at end of period	$ 247,254

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Ancient Investments, LLC
Consulting fees	$ 170,000	$ 184,000
Accrued liability	10,000	15,000
Edward DeFeudis
Consulting fees	102,000	122,000
Accrued liability	5,000	0
AMP Web Services
Consulting fees	56,000	86,000
Accrued liability	0	7,000
Keystone Business Development Partners [Member]
Consulting fees	25,000	40,425
Accrued liability	$ 5,000	$ 0

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended							3 Months Ended	9 Months Ended	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Mar. 01, 2022	Aug. 10, 2021	Mar. 20, 2022	Jan. 20, 2022	Aug. 20, 2021	Aug. 19, 2021	Aug. 09, 2021	Jul. 28, 2021	Jul. 06, 2021	Nov. 10, 2021	May 10, 2022	Jun. 30, 2023	Jun. 30, 2022
Common shares cash amount paid per meeting												$ 0	$ 2,078,500
Stock issued during priod shares new issues												945,731,070	908,862,990
Financial Advisory Agreements One [Member]
Stock issued during priod shares new issues						2,225,000
Issue of initial shares													1,500,000
Issue common shares payable						2,225,000
Cash fee percent of amount capital raised						7%							7%
Financial Advisory Agreements [Member]
Stock issued during priod shares new issues										500,000	500,000
Issue of initial shares													2,225,000
Issued share payable		500,000
Financing fees description												Pay a financing fee of 1.5% of gross proceeds received by the Company up to $100,000,000; a financing fee of 1.25% of gross proceeds received by the Company from $100,000,000-$200,000,000, and a financing fee of 1% of gross proceeds received by the Company over $200,000,000
M A Description						Pay a cash fee for entering into a transaction including, without limitation, a merger, acquisition or sale of stock or assets equal to one- and one-half percent (1.5%), or in the event a transaction is consummated with a party that was in communication with the Company prior to the date of this contract, then the fee shall equal one half percent (0.5%).						M&A fee of 1.5% of the value of a business or asset sold up to $50,000,000; an M&A fee of 1.25% of value of a business or asset sold from $50,000,000-$100,000,000, an M&A fee of 1% of value of a business or asset sold from $100,000,000-$200,000,000, and an M&A fee of 0.5% of value of a business or asset sold over $200,000,000
Advisory Board [Member]
Common shares cash amount paid per meeting	$ 2,500		$ 2,500	$ 2,500	$ 2,500		$ 2,500	$ 2,500	$ 2,500
Stock issued during priod shares new issues	150,000		150,000	150,000	100,000		50,000	250,000
Additional bonus paid common shares issued for services			$ 25,000		$ 25,000			$ 25,000	$ 25,000
Warrant options to common shares					4,000,000			5,000,000	5,000,000
Common stock shares issuedsold price per share					$ 0.12			$ 0.12	$ 0.12
Common share opened a strategic bonus	25,000			25,000			25,000	5,000,000	250,000
Advisory Board [Member] \| July 1 2021 [Member]
Common shares cash amount paid per meeting												$ 2,500
Stock issued during priod shares new issues												100,000
Additional bonus paid common shares issued for services												$ 25,000
Warrant options to common shares												1,000,000
Common stock shares issuedsold price per share												$ 0.12
Average market price												25%
Option to purchase shares												5,000,000
Trading days												10 days
Finders fee												1%

EQUITY (Details)

EQUITY (Details) - USD ($)	12 Months Ended
EQUITY (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Number of Shares
Outstanding, Beginning	21,250,000
Granted		21,250,000
Exercised	21,250,000	21,250,000
Outstanding at Ending	21,250,000	21,250,000
Exercisable at Ending	20,687,500
Weighted Average Exercise Price
Outstanding, Beginning	$ 0.12	$ 0
Granted		0.12
Exercised	0	0
Canceled	0	0
Outstanding at Ending	0.12	$ 0.12
Exercisable at Ending	$ 0.12
Weighted Average Remaining Contractual Term
Outstanding at Ending	1 year 1 month 9 days	2 years 1 month 6 days
Exercisable at Ending	1 year 1 month 9 days
Aggregate Intrinsic Value
Outstanding at Ending	$ 0
Exercisable at Ending	$ 0

EQUITY (Details 1)

EQUITY (Details 1) - Stock Option [Member]	12 Months Ended
EQUITY (Details 1) - Stock Option [Member]	Jun. 30, 2023 $ / shares
Exercise price	$ 0.12
Maximum [Member]
Quoted market price on valuation date	$ 0.23
Range of expected term	2 years 5 months 26 days
Range of interest rate	1.08%
Range of equivalent volatility	275.73%
Minimum [Member]
Quoted market price on valuation date	$ 0.169
Range of expected term	1 year 6 months 18 days
Range of interest rate	0.20%
Range of equivalent volatility	181.21%

EQUITY (Details 2)

EQUITY (Details 2) - $ / shares	12 Months Ended
EQUITY (Details 2) - $ / shares	Jun. 30, 2023	Jun. 30, 2022
Exercised		(4,308,600)
Warrants [Member]
Outstanding, Beginning	55,512,161	8,848,333
Granted	52,700,000	50,968,828
Exercised		(4,305,000)
Canceled	(3,410,000)
Outstanding, Ending	104,802,161	55,512,161
Outstanding Vested and expected to vest, Ending	104,802,161	0
Outstanding Exercisable, Ending balance	104,802,161	0
Weighted average contractual term [Member]
Weighted average contractual term, beginning	5 years 1 day	11 months 8 days
Weighted average contractual term, ending	3 years 9 months 14 days
Weighted average contractual term, Vested and expected to vest	3 years 9 months 14 days
Weighted average contractual term, Exercisable	3 years 9 months 14 days
Weighted average contractual term, granted		4 years 7 months 6 days
Weighted Average Exercise Price [Member]
Weighted average exercise price, beginning	$ 0.1110	$ 0.0300
Weighted average exercise price, granted	0.0865	0.1187
Weighted average exercise price, Ending	0.1015	$ 0.1110
Weighted average exercise price, Vested and expected to vest	0.1015
Weighted average exercise price, Exercisable	$ 0.1015

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)		1 Months Ended			12 Months Ended
EQUITY (Details Narrative) - USD ($)	Jul. 11, 2022	Mar. 26, 2023	Mar. 17, 2023	Oct. 24, 2022	Jun. 30, 2023	Jun. 30, 2022
Common stock authorized					5,000,000,000	5,000,000,000
Common stock shares par value					$ 0.00001	$ 0.00001
Common stock shares issued					389,433,144	365,239,001
Common stock shares outstanding					389,433,144	365,239,001
Shares issued for common stock in exchange for the inducement						845,936
Conversion of Stock in Principle amount						$ 167,550
Conversion of Stock in accured interest						4,984
Loss on an extinguishment						$ 536
Common stock issued for prior period conversions of principal and interest						10,598,544
Conversion of convertible notes payable					$ 270,000	$ 250,000
Accrued interest						$ 3,749
Common stock share issued for conversion						4,229,680
Aggregate relative fair value						$ 134,929
Stock issued during period shares issued for services					457,143	4,685,615
Stock issued during period value issued for services					$ 48,000	$ 761,954
Share sold during period, shares						39,366,666
Share sold during period, value						$ 2,078,501
Aggregate gross proceeds on exercise of warrant						$ 128,550
Number of warrants exercised						4,308,600
Number of warrants Outstanding					104,802,161	55,512,161
Number of shares Options outstanding					21,250,000	21,250,000
Number of shares Stock options exercisable					20,687,500
Stock options issued						21,250,000
Exercise price						$ 0.12
Stock issued during priod shares new issues					945,731,070	908,862,990
Common shares issued during period value						$ 2,078,501
Subscription Agreement [Member]
Stock issued during priod shares new issues						250,000
Common shares issued during period value						$ 43,753
Series B Preferred Shares [Member]
Preferred stock shares authorized					100,000,000	100,000,000
Preferred stock shares par value					$ 0.00001	$ 0.00001
Preferred stock shares designated					1,000,000	1,000,000
Preferred stock shares issued					1,000,000	1,000,000
Preferred stock shares outstanding					1,000,000	1,000,000
Series A Preferred Stock shares 1 [Member]
Share issued for exchange conversion, shares					10,237,000	7,138,000
Conversion of Series A Preferred to Common Stock, shares					10,237	7,138
Series A Preferred Stock shares [Member]
Share issued for exchange conversion, shares	1,000,000	7,500,000	5,000,000	10,237,000	1,000,000
Conversion of Series A Preferred to Common Stock, shares	1,000	7,500	5,000	10,237	1,000
Preferred stock shares authorized					100,000,000	100,000,000
Preferred stock shares par value					$ 0.00001	$ 0.00001
Preferred stock shares designated					3,500,000	3,500,000
Voting description					1,000 votes to every one share of common stock
Conversion description					1:1,000
Preferred stock shares issued					757,395	781,132
Series A Preferred Stock shares 2 [Member]
Share issued for exchange conversion, shares					5,000,000
Conversion of Series A Preferred to Common Stock, shares					500
Series A Preferred Stock shares 3 [Member]
Share issued for exchange conversion, shares					7,500,000
Conversion of Series A Preferred to Common Stock, shares					7,500
Warrants [Member]
Aggregate gross proceeds on exercise of warrant						$ 128,550
Number of warrants exercised						4,305,000
Number of warrants exercised						4,308,600
Number of warrants Outstanding					104,802,161	55,512,161
Wighted average remaining useful life of warrants					3 years 9 months 14 days
Stock Option [Member]
Number of shares Options outstanding					21,250,000
Number of shares Stock options exercisable					20,687,500
Stock options weighted average remaining term					1 year 1 month 9 days
Compensation expense					$ 702,116	$ 3,248,181
Fair value of stock option					$ 3,964,207
Stock options issued					21,250,000
Exercise price					$ 0.12
Total unrecognized compensation					$ 0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Deferred income tax asset
Net operation loss carryforwards	$ 7,460,414	$ 5,860,409
Valuation Allowance	(7,460,414)	(5,860,409)
Net Deferred Tax Asset (Liability)	$ 0	$ 0

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 12, 2023	Jun. 30, 2022
Convertible notes issued		$ 4,984
Subsequent Event [Member]
Convertible notes issued	$ 461,000